Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration

Indian Journal of Critical Care Medicine

Volumn 18, Issue 7, 2014, Pages 427-430

  Dewan, Arun ^a   Shoukat, Mujeeb ^a  

^a Batra Hospital India   (India)

Author keywords

Extended interval; High dose colistin; nephrotoxicity

Indexed keywords

COLISTIN;

ACINETOBACTER BAUMANNII; ACUTE KIDNEY FAILURE; AGED; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG MEGADOSE; FEMALE; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MULTIDRUG RESISTANCE; NEPHROTOXICITY; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PSEUDOMONAS; RENAL REPLACEMENT THERAPY; SEPSIS; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84905646979     PISSN: 09725229     EISSN: 1998359X     Source Type: Journal    
DOI: 10.4103/0972-5229.136070     Document Type: Article

References (21)

1. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010;54:4503-5.
2. Michalopoulos AS, Falagas ME. Colistin: Recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ann Intensive Care 2011;1:30.
3. Kumazawa J, Yagisawa M. The history of antibiotics: The Japanese story. J Infect Chemother 2002;8:125-33.
4. Falagas ME, Kasiakou SK. Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-41.
5. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: The re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
6. Daikos GL, Skiada A, Pavleas J, Vafiadi C, Salatas K, Tofas P, et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother 2010;22:175-8.
7. Beringer P. The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 2001;7:434-40.
8. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother 2005;49:3136-46.
9. Michalopoulos AS, Karatza DC, Gregorakos L. Pharmacokinetic evaluation of colistin sodium. Expert Opin Drug Metab Toxicol 2011;7:245-55.
10. Bergen PJ, Li J, Nation RL. Dosing of colistin-back to basic PK/PD. Curr Opin Pharmacol 2011;11:464-9.
11. Markou N, Apostolakos H, Koumoudiou C, Athanasiou M, Koutsoukou A, Alamanos I, et al. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003;7:R78-83.
12. Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: Population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 2012;56:4241-9.
13. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract 2008;109:c182-7.
14. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009;64 Suppl 1:i3-10.
15. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and efficacy of intravenous colistin (colistin methanesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010;35:297-300.
16. Markou N, Markantonis SL, Dimitrakis E, Panidis D, Boutzouka E, Karatzas S, et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: A prospective, open-label, uncontrolled study. Clin Ther 2008;30:143-51.
17. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 2010;138:1333-9.
18. Garonzik SM, Li J, Thamlikitkul V, Pason DL, Shoham S, Jacob J et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011;55:3284-94.
19. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009;53:3430-6.
20. Berg JR, Spilker CM, Lewis SA. Effects of polymyxin B on mammalian urinary bladder. J Membr Biol 1996;154:119-30.
21. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: A prospective evaluation. Int J Antimicrob Agents 2005;26:504-7.